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Abstract

CD4
+ Natural Killer T (NKT) cells along with CD4 + CD25 + regulatory T cells (Treg) are capable of controlling aberrant immune reactions. We explored the adoptive transfer of highly purified (>95%) CD4 + NKT cells in a murine model of allogeneic hematopoietic cell transplantation (HCT). NKT cells follow a migration and proliferation pattern similar to conventional T cells (Tcon) migrating initially to secondary lymphoid organs followed by infiltration of GVHD target tissues. NKT cells persist for over 100 days and do not cause significant morbidity nor mortality. Doses of NKT cells as low 1.0x10 4 cells suppress GVHD caused by 5.0x10 5 Tcon in an IL-4-dependent mechanism. Protective doses of NKT cells minimally impact Tcon proliferation, but cause significant reductions in IFN-γ and TNF-α production by donor Tcon and significant reductions in skin, spleen, and gastrointestinal pathology. Also, NKT cells do not impact the graft-versus-tumor (GVT) effect of Tcon against the BCL-1 tumor. These studies elucidate the biological function of donor-type CD4 + NKT cells in suppressing GVHD in an allogeneic transplant setting, demonstrating clinical potential in reducing GVHD in HCT.
Introduction
Allogeneic hematopoietic cell transplantation (HCT) is a successful therapy for both malignant and nonmalignant diseases. Immunological reactions are central to the beneficial effects of HCT resulting in engraftment and disease control; however, a major limitation of HCT is acute graftversus-host disease (aGVHD), characterized by immunodysregulation and injury of tissues including the skin, gastrointestinal tract and liver 1 . Much work has focused on the use of CD4 + CD25
+ regulatory T cells (Treg) in the control of GVHD, and adoptive transfer of Treg can prevent or ameliorate GVHD, while preserving the graft-versus-tumor (GVT) effect [2] [3] [4] [5] [6] [7] [8] [9] . While multiple mechanisms have been proposed, the net effect is that Treg consistently suppress the alloreactive T cell proliferation critical for GVHD induction and disease progression.
NKT cells, which express NK and T cell markers, have also shown potential to regulate immune reactions. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation and depletive anti-T cell Abs corresponded with an increase in host-type DX5 + TCRαβ + NKT cells 10 . Furthermore, marrow derived NK1.1 + T cells ameliorate GVHD in an IL-4 dependent manner 11 . This concept has been translated to the clinic with a very low rate of acute GVHD and transplant related mortality 12, 13 . Others have found that invariant NKT cells (iNKT), expanded in vitro with the ligand, α-GalCer, prolonged survival in allogeneic transplant models as could administration of α-GalCer 14, 15 . In contrast, using whole bone marrow from a variety of knock-out mice, Kim et al. reported that BM type II NKT cells (rather than iNKT) suppressed GVHD and prolonged survival in mice by mechanisms involving both IFN-γ and IL-4 production by BM type II NKT cells 16 .
In this study, we examined the migration, proliferation, and regulatory capability of unmanipulated donor-type CD4 + NKT cells in a major-MHC mismatch murine model of GVHD. This is the first study to examine the effect of un-manipulated (i.e. not stimulated in vitro with α-GalCer) donor NKT cells consisting of both invariant and non-invariant populations. Furthermore, while previous studies transferred total iNKT cells, we chose to examine CD4 + NKT cells as they have been shown to produce much more IL-4 than CD4 -NKT cells [17] [18] [19] [20] [21] [22] . We non-invasively and longitudinally monitored the in vivo trafficking properties of CD4 + NKT cells and evaluated their ability to suppress GVHD. We found that administration of small numbers of NKT cells (in relation to the GVHD-inducing conventional T cells) significantly reduced GVHD-related tissue damage and improved survival. The mechanism of NKT cell mediated suppression of GVHD was examined as was the effect of NKT cells on the graft-versus tumor (GVT) effect of HCT. 
Materials and Methods
Mice
Intracellular cytokine Staining
Cells were stimulated with phorbol myristate acetate (PMA) (40 ng/ml), ionomycin (2 μM) and monensin (2 μM) (Sigma-Aldrich, St Louis, MO), for 5 hours at 37˚C and 5% CO 2 in complete RPMI (cRPMI) with 10% FCS, 2mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin (Invitrogen), and 5 µg/mL 2-mercaptoethanol (Sigma-Aldrich). Unstimulated controls were incubated in cRPMI only. After staining surface antigens and with EMA, cells were fixed and permeabilized (BD Biosciences, San Diego, CA), and assessed for IL-2, IL-4, IL-5, IL-10, IL17, IFN-γ, or TNF-α. 
In vivo and ex vivo bioluminescence imaging
Bioluminescence imaging was performed as described 24 with an IVIS 7, IVIS 29, or IVIS Spectrum charge-coupled device (CCD) imaging system (Xenogen, Alameda, CA). Images were analyzed with Living Image Software 2.5 (Xenogen) and Igor Pro Carbon (Wavemetrics, Lake Oswego, OR).
Histopathology
Tissues were fixed in 10% neutral buffered formalin, and four-micron-thick, formalin-fixed, paraffin-embedded sections stained with hematoxylin and eosin, and evaluated by an experienced pathologist (R.H.L.), who was blinded to the experimental groups. Stained tissue sections were evaluated with an Olympus BX-41 microscope with a Canon Powershot G9 camera and Zeiss AxioVision 4.7 digital imaging software.
Statistical analysis
Differences in animal survival (Kaplan-Meier survival curves) were analyzed by log-rank test. All other comparisons were performed with the 2-tailed Student t test and a P value of less than .05 was considered statistically significant.
Results
NKT cells follow a migration pattern typical of conventional T cells, but do not cause GVHD.
We examined the migration and proliferation of donor-type luc + NKT cells in a transplantation setting. CD4 + NKT cells were purified from pooled spleen and liver cells to greater than 95% purity ( Figure 1A ). NKT cells were approximately 50% positive for CD1d-PBS-57 tetramer, indicating that the purified cells include both invariant and non-invariant NKT cells. Figure 1B) . BLI analysis showed localization of NKT cells in the spleen and lymph nodes (LNs) by day 4 after transfer, and between days 7 and 10 NKT cells migrate to the skin ( Figure 1C ). Total photons emitted peaked around day 25 after transplantation, followed by a steady decline. NKT cells persisted in observable numbers for more than 160 days. Ex vivo BLI imaging indicated that early BLI signals were primarily from spleen and LNs and at later time points NKT cells migrated into GVHD target organs such as the gastrointestinal tract and liver ( Figure 1D ). Taken together these results indicate that NKT cells themselves do not cause any observable morbidity or mortality and that they follow a similar migration pattern to that of conventional CD4 or CD8 T cells (Tcon) 25 .
Low doses of NKT cells have a protective effect against GVHD
To assess the impact of donor-type NKT cells on GVHD induction by Tcon, we co-transferred various doses of highly purified wild-type (WT) NKT cells from C57BL/6 mice on day 0 with 5x10 6 TCD-BM, followed by 5x10 5 luc + Tcon on day 2 into irradiated allogeneic Balb/c recipients. In the absence of NKT cells, mice develop GVHD, with only 20% of mice surviving past 100 days ( Figure 2A ). However, the addition of 2.5x10 4 NKT cells improved survival to 74% (p=0.002 compared to Tcon only). Improvement in survival was also observed with a dose of 1.0x10 4 NKT cells with 68% of mice surviving beyond 100 days (p=0.006 compared to Tcon only). Interestingly, increasing the dose of NKT cells to 5x10 4 or 1x10 5 cells per animal resulted in lesser reduction of GVHD than with the lower NKT cell doses with only 33% and 45% of mice surviving, respectively. Thus, the doses of 5x10 4 and 1x10 Tcon (44% versus 20% survival at day 100, respectively; p=0.02 for invariant and p=0.04 for non-invariant as compared to Tcon alone) indicating both of these subsets of NKT cells contribute to the suppression of GVHD-associated mortality.
Histologic analysis of formalin-fixed, paraffin-embedded tissues (haired skin, small and large intestines, liver, thymus, spleen, and mesenteric lymph nodes) revealed some significant differences in the occurrence and/or severity of pathology consistent with acute GVHD in mice receiving NKT cells and Tcon compared to animals that only received Tcon cells ( Figure 2C ). For example, epidermal manifestations of acute GVHD (epidermal hyperplasia, interface dermatitis with apoptotic bodies, dermal fibrosis, dermal inflammation, panniculitis, follicular inflammation and/or loss) were observed in the mice receiving Tcon cells only, but were altogether absent in the mice receiving 2.5x10 4 or 1x10 5 NKT cells. Similarly, while no observable lesions were noted in the small intestines or livers of the mice receiving 2.5x10 4 or 1x10 5 NKT cells, lymphocytic enteritis and portal hepatitis was noted in mice receiving Tcon only. All Tcon-only mice also consistently presented with moderate to marked lymphocytic colitis with increased apoptosis in crypt enterocytes; however, these findings were greatly reduced in mice which received 2.5x10 4 or 1x10 5 NKT cells. Interestingly, no observable changes were noted in the thymi or mesenteric lymph nodes between all groups, although atrophy of lymphoid follicles in the splenic white pulp areas was consistently less severe in the mice receiving Tcon cells and 2.5x10 4 or 1x10 5 NKT cells compared to mice receiving Tcon cells only.
Unlike CD4 + CD25 + regulatory cells, NKT cells minimally impact the proliferation of conventional CD4 or CD8 cells at doses which reduce GVHD
To further examine the mechanism by which NKT cells may be decreasing GVHD and improving the survival of mice receiving allogeneic Tcon, we examined the effect of NKT cells on the proliferation of Tcon, compared to doses of Treg which suppress GVHD. Using the same allogeneic transplant model as above, we observed, via quantitation of BLI signal from 5x10 We know from previous work with Tregs that these cells result in considerable suppression of Tcon proliferation [7] [8] [9] 26 to reduce the manifestations of GVHD. Thus, GVHD amelioration and improved survival by NKT cells cannot be explained by suppression of proliferation.
NKT cells lower the percentage of Tcon producing the pro-inflammatory cytokines IFN-γ and TNF-α
As we have demonstrated that NKT cells have minimal effects on the proliferation of Tcon, we hypothesized that NKT cells must function through an alternate mechanism. We examined intracellular levels of various cytokines secreted by Tcon in the presence or absence of 2.5x10 4 NKT cells following transplantation. The most significant changes (p<0.0001) were observed in the percentages of Tcon expressing the pro-inflammatory Th1 cytokine IFN-γ ( Figure 4A ). In lymph node (LN) at Day 11 post-transplant, the presence of 2.5x10 4 NKT cells caused a reduction in the IFN-γ-expressing population from 80% and 84% in CD4 and CD8 cells to 42% and 47%, respectively. Decrease in the IFN-γ positive population was also observed in liver and spleen (spln) at day 8 with the NKT cells causing the percent of IFN-γ positive CD4 cells to decrease from 80% to 62% and from 80% to 72% in liver and spleen, respectively. Similarly, the decrease in IFN-γ positive CD8 cells was also decreased in the presence of NKT cells from 79% to 55% and from 66% to 55% in liver and spleen, respectively.
Significant changes (p<0.0001) were also observed in the percentages of donor Tcon expressing another pro-inflammatory Th1 cytokine, TNF-α ( Figure 4B ). At 8 days after transplantation, mice receiving NKT cells had fewer TNF-α-expressing cells in LNs (CD4: 52% vs 32%; CD8 36% vs 24%). Similar decreases were also observed in the liver at day 8 and spleen at day 11. The percentages of liver lymphocytes expressing TNF-α were decreased at day 8 from 30% vs 10% and from 7% vs 2% in CD4 and CD8 cells, respectively. The percentages of splenic donor Tcon expressing TNF-α was also reduced at day 11 from 27% vs 16% and 15% vs 10% in CD4 and CD8 cells, respectively.
Significant differences were not observed in the cytokine profiles of IL-2, IL-4, IL-5, IL-10, and IL-17 producing cells (data not shown). Taken together, these results indicate that the presence of NKT cells results in an alteration in the cytokine profile of both CD4 and CD8 Tcon resulting in fewer T cells producing IFN-γ and TNF-α during the course of GVHD.
Mechanism of NKT cell suppression of GVHD involves IL-4 production by NKT cells
As IL-4 and IFN-γ are the two primary cytokines produced by NKT cells [27] [28] [29] , we examined whether the suppression of GVHD by NKT cells is dependent on the production of either of these two cytokines. In the same transplantation model used above, we co-transferred 1.0x10 4 FACS sorted NKT cells (purity >95%) from either wild-type or IL-4 -/-KO donor mice (all C57BL/6 background) with 5x10 6 TCD-BM, followed by Tcon on day 2. NKT cells from IL-4 -/-KO mice were significantly less effective at suppressing GVHD than wild-type NKT cells ( Figure 5 ; p = 0.02). No significant decrease in protection against GVHD was observed from the transfer of NKT from IFN-γ -/-KO mice as compared to WT NKT cells (data not shown). Thus, IL-4 production but not IFN-γ production by NKT cells is an essential component in the suppressive mechanism of NKT cells.
Presence of NKT cells does not interfere with tumor clearance by Tcon
As HCT is often utilized to treat hematologic malignancies, we examined whether NKT cells impact clearance of tumor by Tcon. Using the same allogeneic transplant model as described above, we transferred either 2.5x10 4 NKT cells alone, 5.0x10 5 Tcon alone, or these two populations together into Balb/c recipients which had luc + Bcl-1 lymphoma cells introduced 7
For (Figure 6 ). Mice receiving TCD-BM alone had strong BLI signals from their tumors. The addition of 2.5x10 4 NKT cells alone caused some reduction in tumor burden; however, complete tumor clearance was obtained only when mice received either Tcon or Tcon+NKT cells ( Figure 6A ). This is also shown in Figure 6B where the luc + Bcl-1 tumor burden is initially reduced due to radiation, but then becomes re-established by days 7-9, except in the groups receiving either Tcon alone or Tcon+NKT cells ( Figure 6B, P<0.0001) . Interestingly, when mice were treated with Tcon and tumor together, improvement in overall survival was not observed with the addition of NKT cells as these animals continued to have complete tumor clearance but were more likely to die from GVHD long term, suggesting that NKT regulation of GVHD may be attenuated in the presence of tumor (data not shown). Together, these results indicate that the GVT effect is intact in the presence of NKT cells, and that the NKT cells themselves may contribute some modest anti-tumor activity.
Discussion
In this study we examined the impact of adoptive transfer of highly purified populations of NKT cells in a well-established murine model of major MHC-mismatched HCT. This is the first study to demonstrate the trafficking and survival of NKT cells following adoptive transfer in an allogeneic transplantation model. We observed a robust expansion of NKT cells in secondary lymphoid organs, followed by migration to GVHD target organs in a pattern similar to that of Tcon 25 . NKT cells had remarkably long survival yet importantly did not cause any significant mortality unlike conventional CD4 and CD8 cells which induce lethal acute GVHD at similar cell doses.
We observed that transfer of very low numbers of donor NKT cells suppressed GVHD and improved survival past day 100, and involved both invariant and non-invariant NKT cells. Interestingly, the dose of NKT cells that was 1/20 th of the Tcon dose was found to be the most protective, and increasing the dose of NKT cells to 1/10 th or 1/5 th of the Tcon dose resulted in less improvement in survival. These differences are also reflected in the pathology of the skin and gastrointestinal tract, where mice receiving Tcon alone had moderate to severe lymphocytic colitis, increased crypt enterocytes, apoptotic bodies, and other manifestations of acute GVHD. Mice receiving a low dose of NKT cells had relatively healthy appearing GI tracts with almost no signs of GVHD. Mice receiving a high dose of NKT cells, however, had pathology intermediate to that of the low dose of NKT cells and the Tcon only group. Together, the survival and pathology data suggests that NKT cells may have a yet to be determined "side effect" that is detrimental to the mice when NKT cells are given at higher doses. However, we have shown that mice can receive 5.5x10 5 NKT cells alone without any increased morbidity or mortality; thus, if high doses of NKT cells cause adverse effects, these effects are dependent on the presence of GVHD-inducing Tcon. The reasons why the higher doses of NKT cells were less effective at suppressing GVHD are thus likely to be complex and are beyond the scope of this study. However, we could speculate that since NKT cells are potent producers of IFN-γ 19 , that they might contribute to Tcon-mediated gastrointestinal pathology at high doses.
Interestingly, even though small numbers of NKT cells were capable of suppressing GVHD they have little effect on Tcon proliferation. This finding is in marked contrast to the adoptive transfer of CD4 + CD25 + Tregs that also suppress GVHD yet function through the suppression of Tcon proliferation as has been observed in this and previous studies 7, 8 . CD4 + CD25 + Tregs suppress both Tcon proliferation and consequently, GVHD with more potency as their numbers are increased. Thus, we concluded that NKT cells must ameliorate GVHD via a different mechanism. Furthermore, NKT cells had an optimal dose of just 1-2.5x10 4 cells, which is considerably less than has been observed in previous studies with Treg, which typically require 5x10 5 cells for biological activity in this same strain combination.
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Production of pro-inflammatory Th-1 cytokines IFN-γ and TNF-α by Tcon are important in GVHD pathophysiology. Reports from both murine and human studies indicate that massive cytokine release related to the Th-1 phenotype of alloreactive T cells predicts the incidence and severity of acute GVHD 30 . Also, Th-1/Th-2 polarization of T-helper cell subsets impacts the development of GVHD, determining end organ damage 31 . Following myeloablative conditioning and transfer of Tcon, several changes occur in the gastrointestinal tract. Initially, there is proliferation which results in crypt lengthening and increased intraepithelial lymphocytes, linked to IFN-γ production 32 . IFN-γ increases MHC class II expression and gut permabiltiy 33 and possibly affects crypt stem-cell turnover 34 . Inhibiting IFN-γ reduces gut pathology in animals with GVHD 35 . IFN-γ production by Tcon also primes monocytes and macrophages making them sensitive to LPS in the gut 36 (released by radiation and T-cell induced damage) . These cells then produce TNF-α which is directly toxic to the gut during GVHD [37] [38] [39] . Therefore, a variety of strategies have been explored to alter the pro-inflammatory function of donor Tcon which have impacted GVHD severity 26, 35, [39] [40] [41] . Importantly, NKT cells significantly and consistently down-regulated the production of pro-inflammatory IFN-γ and TNF-α by Tcon. Thus, it is not surprising that addition of NKT cells results in healthier gastrointestinal tracts and improved survival.
This decrease in the Th-1 type cytokines IFN-γ and TNF-α in the donor Tcon population suggested that the effect of NKT cells may be attributed to their ability to produce IL-4. In fact, this appears to be the case. NKT cells from IL-4 -/-KO mice were significantly less effective in suppressing GVHD than wild-type NKT cells. This result is consistent with findings from other groups that have also found IL-4 to be a mechanism by which NKT cells may suppress GVHD 11, 16 . Furthermore, stimulation of recipient mice with the NKT ligand α-GalCer has also been shown to reduce GVHD in a mechanism dependent on IL-4 production by recipient NKT cells.
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Also, several groups have found that adoptive transfer of IL-4-producing, Th2-polarized cells,
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From can reduce GVHD. [43] [44] [45] [46] [47] As the mechanism of NKT cell suppression of GVHD is dependent on IL-4, we expected to see more Th2-type IL-4 expressing T cells in the presence of NKT; however, at this early point in GVHD induction we are primarily observing high levels of IFN-γ and TNF-α, and most T cells present in the mouse are not naïve. Thus, it would likely take more time for Th0 progenitors to be induced towards a Th2, IL-4 producing phenotype, if this were to occur. Nevertheless, we believe that the decrease in Th1 cytokine producing cells (including the inhibition of the formation of new Th1 cells), is sufficient to decrease GVHD without an increase in a Th2 population. In contrast to the findings by Kim et al. 16 that found IFN-γ-producing BM type II NKT cells suppress GVHD by inducing the apoptosis of donor T cells, we did not find IFN-γ -/-KO NKT cells to be significantly less effective than wt NKT cells in suppressing GVHD in our model.
As HCT is commonly used as therapy for hematologic malignancies, we assessed whether NKT cell regulation of Tcon would impact the GVT effect of Tcon. We found that the addition of NKT cells alone caused some reduction in tumor burden in contrast to Treg which do not have any significant anti-tumor activity 7 ; however, complete tumor clearance was obtained only when mice received both Tcon in addition to the NKT cells. These results indicate that the GVT effect is intact in the presence of NKT cells, and that the NKT cells themselves may provide some antitumor activity. This is consistent with numerous reports in the literature that NKT cells, particularly invariant NKT cells, have anti-tumor activity 48 . However, we did not find survival to be improved by NKT cells in the presence of both Tcon and tumor as in the presence of tumor the ability of NKT cells to protect against GVHD was reduced.
In conclusion, we have shown the proliferation and migration of CD4 + NKT cells in a model of allogeneic bone marrow transplantation, and found that low doses of NKT cells ameliorate GVHD pathology and improve animal survival. In contrast to CD4 + CD25 + Treg, NKT cells do not reduce GVHD by suppressing the proliferation of Tcon, but rather act via a mechanism involving IL-4 production and cause a decrease in Th-1-type cytokine production by donor T cells. Furthermore, the addition of NKT cells did not interfere with the graft-versus-tumor effect of conventional T cells. We have also elucidated potential caveats of NKT cells in that they were less effective at higher doses and that their regulatory function may be attenuated in the presence of tumor. These data support the potential therapeutic application of allogeneic NKT cells in clinical allogeneic HCT, but also indicate a need for continued research into the behavior of NKT cells, and their interactions with their environment and other immune cells to gain further insight into immune modulation of GVHD and T cell function. 4.0×10 09
